<p>在過去三個月中，19 位分析師對 Inspire Medical Systems（紐約證券交易所：INSP）發佈了評級，呈現出從看漲到看跌的廣泛觀點。</p>
<p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師為 Inspire Medical Systems 設定了 12 個月的價格目標，顯示出平均目標為 124.11 美元，最高預估為 180.00 美元，最低預估為 70.00 美元。目前的平均價格目標較之前的 127.35 美元下降了 2.54%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png"/></p>
<h2>解讀分析師評級：更深入的觀察</h2>
<p>通過對最近分析師行動的全面分析，描繪出 Inspire Medical Systems 在金融專家中的認知。下面的總結概述了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>下調</td>
<td>超配</td>
<td>$85.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下調</td>
<td>持有</td>
<td>$70.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>下調</td>
<td>超過市場</td>
<td>$85.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>等權重</td>
<td>$70.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>下調</td>
<td>中性</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下調</td>
<td>行業表現</td>
<td>$90.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>超配</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下調</td>
<td>買入</td>
<td>$120.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>上調</td>
<td>中性</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超過市場</td>
<td>$175.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上調</td>
<td>超過市場</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>上調</td>
<td>中性</td>
<td>$118.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>宣佈</td>
<td>超過市場</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>上調</td>
<td>超過市場</td>
<td>$180.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>等權重</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$165.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>宣佈</td>
<td>超過市場</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>上調</td>
<td>買入</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>關鍵洞察：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化作出反應，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 Inspire Medical Systems 最近發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師從定性角度全面評估股票，從 “超過市場” 到 “低於市場”。這些評級傳達了對 Inspire Medical Systems 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師提供對 Inspire Medical Systems 股票未來價值的估計，揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>理解這些分析師評估與關鍵財務指標相結合，可以為 Inspire Medical Systems 的市場地位提供有價值的洞察。保持信息靈通，利用我們的評級表做出深思熟慮的決策。</p>
<p>隨時瞭解 Inspire Medical Systems 的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>發現 Inspire Medical Systems：更深入的觀察</h2>
<p>Inspire Medical Systems Inc 是一家醫療技術公司，專注於開發和商業化針對阻塞性睡眠呼吸暫停（OSA）患者的微創解決方案。它提供 Inspire 系統，這是一種神經刺激技術，為中度至重度阻塞性睡眠呼吸暫停提供安全有效的治療。該公司在美國和歐洲運營，其中大部分收入來自美國。</p>
<h3>解開 Inspire Medical Systems 的財務故事</h3>
<p><strong>市值：</strong> 由於市值受限，該公司在行業平均水平以下。這反映出相對於同行的較小規模。</p>
<p><strong>收入增長：</strong> Inspire Medical Systems 在第三季度表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>10.49%</strong> 的穩健收入增長率。這表明公司的頂線收益顯著增加。與醫療保健行業的其他公司相比，該公司的增長率低於同行的平均水平，面臨挑戰。</p>
<p><strong>淨利潤率：</strong> Inspire Medical Systems 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>4.42%</strong>，展現出強勁的盈利能力和有效的成本管理。</p>
<p><strong>股本回報率（ROE）：</strong> Inspire Medical Systems 的 ROE 表現突出，超過行業平均水平。該公司的 ROE 達到 <strong>1.48%</strong>，展示了對股本資本的有效利用和強勁的財務表現。</p>
<p><strong>資產回報率 (ROA)：</strong> 公司的資產回報率表現突出，超過行業平均水平。公司以 <strong>1.23%</strong> 的令人印象深刻的資產回報率展示了資產的有效利用。</p>
<p><strong>債務管理：</strong> Inspire Medical Systems 的債務與股本比率低於行業平均水平，為 <strong>0.05</strong>，反映出對債務融資的依賴較低以及更為保守的財務策略。</p>
<h2>分析師評級的核心：每位投資者應知曉的事項</h2>
<p>Benzinga 跟蹤 150 家分析師公司並報告他們的股票預期。分析師通常通過預測公司未來的盈利能力，通常是接下來的五年，以及該公司收入來源的風險或可預測性來得出結論。</p>
<p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或在公司有重大更新時進行評級。</p>
<p>一些分析師還會提供增長預估、收益和收入等指標的預測，以進一步指導股票投資。使用分析師評級的投資者應注意，這些專業建議來自人類，可能會存在錯誤。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

納斯達克生物科技指數 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

2 倍做多納斯達克生物技術 ETF - ProShares

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

啟迪醫療

紐交所高增長板生物技術指數 ETF - First Trust

<p>啓迪醫療系統（NYSE:INSP）在過去三個月內收到了 19 位分析師的評級，顯示出看漲和看跌情緒的混合。12 個月的平均目標價為 124.11 美元，較之前的 127.35 美元有所下降。近期的行動包括幾位分析師下調了他們的評級和目標價，而少數分析師則上調了這些指標。該公司專注於治療阻塞性睡眠呼吸暫停的微創解決方案，報告的收入增長率為 10.49%，並保持強勁的盈利能力，淨利潤率為 4.42%。其債務與股本比率低至 0.05，表明其財務管理較為保守</p>

<p>In the preceding three months, 19 analysts have released ratings for Inspire Medical Systems (NYSE: INSP), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，19 位分析師對 Inspire Medical Systems（紐約證券交易所：INSP）發佈了評級，呈現出從看漲到看跌的廣泛觀點。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Inspire Medical Systems, revealing an average target of $124.11, a high estimate of $180.00, and a low estimate of $70.00. A 2.54% drop is evident in the current average compared to the previous average price target of $127.35.</p>
<div class="lb-trans"><p>分析師為 Inspire Medical Systems 設定了 12 個月的價格目標，顯示出平均目標為 124.11 美元，最高預估為 180.00 美元，最低預估為 70.00 美元。目前的平均價格目標較之前的 127.35 美元下降了 2.54%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770901236_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解讀分析師評級：更深入的觀察</h2>
</div><p>A clear picture of Inspire Medical Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的全面分析，描繪出 Inspire Medical Systems 在金融專家中的認知。下面的總結概述了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$118.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>下調</td>
<td>超配</td>
<td>$85.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下調</td>
<td>持有</td>
<td>$70.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>下調</td>
<td>超過市場</td>
<td>$85.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>等權重</td>
<td>$70.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>下調</td>
<td>中性</td>
<td>$74.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下調</td>
<td>行業表現</td>
<td>$90.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>下調</td>
<td>超配</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>下調</td>
<td>買入</td>
<td>$120.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>上調</td>
<td>中性</td>
<td>$91.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超過市場</td>
<td>$175.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>上調</td>
<td>超過市場</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>上調</td>
<td>中性</td>
<td>$118.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$165.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>宣佈</td>
<td>超過市場</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>上調</td>
<td>超過市場</td>
<td>$180.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>等權重</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$165.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>宣佈</td>
<td>超過市場</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>上調</td>
<td>買入</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inspire Medical Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inspire Medical Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Inspire Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師對市場條件和公司表現的變化作出反應，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，反映了他們對 Inspire Medical Systems 最近發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師從定性角度全面評估股票，從 “超過市場” 到 “低於市場”。這些評級傳達了對 Inspire Medical Systems 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師提供對 Inspire Medical Systems 股票未來價值的估計，揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inspire Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解這些分析師評估與關鍵財務指標相結合，可以為 Inspire Medical Systems 的市場地位提供有價值的洞察。保持信息靈通，利用我們的評級表做出深思熟慮的決策。</p>
</div><p>Stay up to date on Inspire Medical Systems analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Inspire Medical Systems 的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>Discovering Inspire Medical Systems: A Closer Look</h2>
<div class="lb-trans"><h2>發現 Inspire Medical Systems：更深入的觀察</h2>
</div><p>Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.</p>
<div class="lb-trans"><p>Inspire Medical Systems Inc 是一家醫療技術公司，專注於開發和商業化針對阻塞性睡眠呼吸暫停（OSA）患者的微創解決方案。它提供 Inspire 系統，這是一種神經刺激技術，為中度至重度阻塞性睡眠呼吸暫停提供安全有效的治療。該公司在美國和歐洲運營，其中大部分收入來自美國。</p>
</div><h3>Unraveling the Financial Story of Inspire Medical Systems</h3>
<div class="lb-trans"><h3>解開 Inspire Medical Systems 的財務故事</h3>
</div><p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值：</strong> 由於市值受限，該公司在行業平均水平以下。這反映出相對於同行的較小規模。</p>
</div><p><strong>Revenue Growth:</strong> Inspire Medical Systems displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>10.49%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Inspire Medical Systems 在第三季度表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>10.49%</strong> 的穩健收入增長率。這表明公司的頂線收益顯著增加。與醫療保健行業的其他公司相比，該公司的增長率低於同行的平均水平，面臨挑戰。</p>
</div><p><strong>Net Margin:</strong> Inspire Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Inspire Medical Systems 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>4.42%</strong>，展現出強勁的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Inspire Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.48%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Inspire Medical Systems 的 ROE 表現突出，超過行業平均水平。該公司的 ROE 達到 <strong>1.48%</strong>，展示了對股本資本的有效利用和強勁的財務表現。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.23%,</strong> the company showcases effective utilization of assets.</p>
<div class="lb-trans"><p><strong>資產回報率 (ROA)：</strong> 公司的資產回報率表現突出，超過行業平均水平。公司以 <strong>1.23%</strong> 的令人印象深刻的資產回報率展示了資產的有效利用。</p>
</div><p><strong>Debt Management:</strong> Inspire Medical Systems's debt-to-equity ratio is below the industry average at <strong>0.05</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Inspire Medical Systems 的債務與股本比率低於行業平均水平，為 <strong>0.05</strong>，反映出對債務融資的依賴較低以及更為保守的財務策略。</p>
</div><h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<div class="lb-trans"><h2>分析師評級的核心：每位投資者應知曉的事項</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟蹤 150 家分析師公司並報告他們的股票預期。分析師通常通過預測公司未來的盈利能力，通常是接下來的五年，以及該公司收入來源的風險或可預測性來得出結論。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或在公司有重大更新時進行評級。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析師還會提供增長預估、收益和收入等指標的預測，以進一步指導股票投資。使用分析師評級的投資者應注意，這些專業建議來自人類，可能會存在錯誤。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

What 19 Analyst Ratings Have To Say About Inspire Medical Systems

benzinga_article

19 位分析師對啓迪醫療系統的評級意見是什麼